These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1193 related items for PubMed ID: 11503270

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cyclooxygenase-2 inhibitors: promise or peril?
    Mengle-Gaw LJ, Schwartz BD.
    Mediators Inflamm; 2002 Oct; 11(5):275-86. PubMed ID: 12467519
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. New NSAIDs and gastroduodenal damage.
    Folco GC.
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
    [Abstract] [Full Text] [Related]

  • 9. Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
    Peek RM.
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S50-6. PubMed ID: 15309515
    [Abstract] [Full Text] [Related]

  • 10. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors.
    Reddy BS, Rao CV.
    J Environ Pathol Toxicol Oncol; 2002 Sep; 21(2):155-64. PubMed ID: 12086402
    [Abstract] [Full Text] [Related]

  • 11. [Clinical data on COX-1 and COX-2 inhibitors: what possible alerts in pharmacovigilance?].
    Larousse C, Veyrac G.
    Therapie; 2000 Sep; 55(1):21-8. PubMed ID: 10859997
    [Abstract] [Full Text] [Related]

  • 12. COX-2-specific inhibition: implications for clinical practice.
    Pascucci RA.
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
    [Abstract] [Full Text] [Related]

  • 13. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S, Sellers LA, Cindrova T, Skepper J, Gherardi E, Sasisekharan R, Fan TP.
    Cancer Res; 2003 Dec 01; 63(23):8351-9. PubMed ID: 14678996
    [Abstract] [Full Text] [Related]

  • 14. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
    Kismet K, Akay MT, Abbasoglu O, Ercan A.
    Cancer Detect Prev; 2004 Dec 01; 28(2):127-42. PubMed ID: 15068837
    [Abstract] [Full Text] [Related]

  • 15. [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma].
    Tuynman JB, Hulscher JB, Steller EP, van Lanschot JJ, Richel DJ.
    Ned Tijdschr Geneeskd; 2003 Nov 08; 147(45):2207-12. PubMed ID: 14640057
    [Abstract] [Full Text] [Related]

  • 16. COX-2 inhibitors. What is their place?
    McGettigan P.
    Aust Fam Physician; 2000 Sep 08; 29(9):847-52. PubMed ID: 11008387
    [Abstract] [Full Text] [Related]

  • 17. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications.
    Pascucci RA.
    J Am Osteopath Assoc; 2002 Sep 08; 102(9):487-9. PubMed ID: 12361181
    [Abstract] [Full Text] [Related]

  • 18. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG.
    Z Gastroenterol; 1999 Jan 08; 37(1):45-58. PubMed ID: 10091284
    [Abstract] [Full Text] [Related]

  • 19. COX-1 and COX-2 inhibitors.
    Hawkey CJ.
    Best Pract Res Clin Gastroenterol; 2001 Oct 08; 15(5):801-20. PubMed ID: 11566042
    [Abstract] [Full Text] [Related]

  • 20. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs.
    Shaheen NJ, Straus WL, Sandler RS.
    Cancer; 2002 Feb 15; 94(4):950-63. PubMed ID: 11920463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.